Updates

July 31, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), Mumbai – P.J. Towers, Dalal Street, 400 051 Mumbai – 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 36/26-27 Our Reference No. 36/26-27 Dear Sir/ Madam, Sub: Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – List of Officials Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”), we would like to inform you that the Board of Directors of the Company in the meeting held on Friday, July 31, 2026 at 4:00 p.m. approved the amendments to Policy on Determination of Materiality for Disclosures. Further, the Company’s officials authorised for the purpose of determining materiality of an event or information and making disclosures to the stock exchange(s) under the Listing Regulation is as under: Sr. Name & Designation Contact Details No. Designation 1. Mr. Glenn Saldanha Chairman & Managing Glenmark Pharmaceuticals Limited Director Add.: Glenmark House, B D Sawant Marg, 2. Mrs. Cherylann Executive Director – Andheri (E), Mumbai 400 099 Pinto Corporate Services 3. Mr. Anurag Mantri Executive Director & Global Tel No.: 91 22 4018 9999 Chief Financial Officer 4. Ms. Rashmi Company Secretary & Email ID: Khandelwal Compliance Officer complianceofficer@glenmarkpharma.com For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS – 28839 Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E:complianceofficer@glenmarkpharma.com